The Johnson & Johnson COVID vaccine halt: here's what investors need to know

Officials are investigating "severe" blood clots in some people.

| More on:
health worker holding a vaccine in their hand

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Johnson & Johnson (NYSE: JNJ) has what many Americans want: a one-dose COVID-19 vaccine. I know people who waited on vaccination specifically to get the J&J jab. The U.S. Food and Drug Administration (FDA) granted the company Emergency Use Authorization in late February. That's two months after the authorization of two-dose vaccines from Pfizer and Moderna. And last month the U.S. ordered an additional 100 million J&J doses. It ordered an initial 100 million doses last year.

The momentum slammed to a halt this week, though. The FDA and the Centers for Disease Control and Prevention (CDC) recommended a pause in the administration of the J&J vaccine after the occurrence of "rare and severe" blood clots in some people. Now investors may be wondering what this means for J&J's future in the vaccine space -- and its share price. Here's what you need to know.

A rare occurence

First, we should put the situation into perspective. J&J has vaccinated more than 6.8 million people in the U.S. so far. Six cases of blood clots have been reported. So this remains an exceptionally rare occurrence. The FDA says it recommends the halt "out of an abundance of caution."

The CDC is meeting with an immunization practices advisory committee on Wednesday to examine the cases. And the FDA is also investigating. The agencies recommend the vaccination halt until their review is complete.

The people who experienced the blood clots were women between the ages of 18 and 48. Symptoms appeared six to 13 days after vaccination. The blood clots -- cerebral venous sinus thrombosis -- are of a type usually treated with the anticoagulant drug heparin. But health officials say that in these cases heparin could be dangerous -- and that means a different treatment must be used.

It's impossible to predict the review's outcome. But we can use the clues we have to imagine potential scenarios.

Considering there is a pattern so far -- women in a certain age group -- the agencies may allow vaccination to resume in those who aren't in this group. It's also possible the agencies will learn why the clotting events occurred and how to prevent them in the future. In that case, vaccination might resume in everyone age 18 and older.

It's also possible experts won't learn exactly why these events occurred. But due to their rarity, the agencies may allow vaccinations in all groups to resume -- as long as healthcare providers have a blood clot treatment plan in place.

"Recognition and management"

The FDA emphasized the idea of awareness among practitioners. The agency said the vaccination pause is important "to ensure that the healthcare provider community is aware of the potential for these adverse events and can plan for proper recognition and management."

So I'm optimistic this is about developing the best plan of use for the J&J vaccine -- not about taking it off the market.

Now, investors may be wondering what this pause means for J&J earnings. The answer is: nothing. J&J has pledged to sell its vaccine without taking a profit during the pandemic. This means any dip in vaccine use or sales won't hurt earnings.

J&J may raise the price of its vaccine after the pandemic is over -- in which case gains or declines in sales will add to or reduce profit. But even at that point, J&J investors shouldn't expect a huge impact. The company's vast array of products means it doesn't rely on just one for revenue or sales growth. For instance, J&J's full-year 2020 revenue totaled more than $82 billion. And the company's products span the categories of consumer health, pharmaceuticals, and medical devices.

How about share price? The shares may dip in the short term on this pause in vaccination. But I don't expect any declines to last for very long. Pharmaceutical stocks haven't been as sensitive to vaccine news as biotech stocks. Again, that's because they don't depend on just one product. So J&J shares remain a solid healthcare investment for the long term.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. recommends Johnson & Johnson and Moderna Inc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on International Stock News

A woman is excited as she reads the latest rumour on her phone.
Broker Notes

Goldman Sachs says this US stock is replacing Tesla in the Magnificent Seven

And no, it's not a tech company. It's in the healthcare sector.

Read more »

A man looking at his laptop and thinking.
Share Gainers

Should I buy Nvidia stock as an Australian investor?

Many Aussies are thinking of jumping on the bandwagon, but they need to think about these issues first.

Read more »

Digital rocket on a laptop.
Broker Notes

Is the Nvidia share price on course to reach US$1,400?

You betcha, says one analyst.

Read more »

A woman holds a soldering tool as she sits in front of a computer screen while working on the manufacturing of technology equipment in a laboratory environment.
International Stock News

Could Nvidia become the most valuable stock on earth?

Can anything stop the Nvidia stock price?

Read more »

A group of young ASX investors sitting around a laptop with an older lady standing behind them explaining how investing works.
International Stock News

What can ASX investors learn from Warren Buffett's latest buys and sells?

We've just found out what Buffett's been buying and selling recently.

Read more »

electric vehicle such as Tesla being charged at charging station
International Stock News

Why Tesla stock tanked in January

Will the electric vehicle leader see earnings decline once again in 2024?

Read more »

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
International Stock News

Will Nvidia stock be worth more than Microsoft by 2030?

The graphics giant has been growing at a much faster pace than Microsoft, but can it sustain that momentum?

Read more »

Man with hands in the middle of two items with money bags on them.
International Stock News

Stock-split watch: Is Tesla next?

Stock splits are fun. But how much substance there is in Tesla splitting its stock is debatable.

Read more »